dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
Serendipity Zapanta RinonosTie LiSean Thomas PiankaTerry J PrinsBlaine S C EldredBryan M KevanLinda M LiauPhioanh Leia NghiemphuTimothy F CloughesyAlbert LaiPublished in: Journal of neuro-oncology (2024)
dCas9/CRISPR is a viable method of epigenetic editing, using the DNMT3A catalytic domain. This study provides initial proof-of-principle for CRISPR technology applications in malignant glioma, laying groundwork for subsequent translational studies, with implications for future epigenetic editing-based clinical applications.